TL;DR
Get health and wellness essentials delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Moderna’s mRNA flu vaccine, mFlusiva, is approved for adults 50 and older, but the company planned a limited first-year launch after its August approval came too late for many pharmacy orders. Moderna says it is available at more than 13,000 locations; use the company’s vaccine finder or call local pharmacies to check availability. Evidence comparing its clinical protection with enhanced flu vaccines remains limited.
Moderna’s mRNA flu vaccine, mFlusiva, is available at more than 13,000 locations, but supplies are limited during its first season, according to the company and experts cited by MedPage Today. Adults ages 50 and older who want the shot can use Moderna’s vaccine finder or call pharmacies, since many retailers had ordered their seasonal flu vaccines before the FDA approved mFlusiva in August. For broader seasonal flu guidance, see why now is an ideal time for flu protection.
Moderna described the rollout as a “limited launch in year one”, a company spokesperson told MedPage Today. The spokesperson said the vaccine is offered at more than 13,000 locations and directed readers to the company’s vaccine finder. Availability at a listed location may still need to be checked, so calling ahead can help confirm whether a pharmacy has doses and can administer the shot.
Amesh Adalja, MD, of the Johns Hopkins Center for Health Security, said people seeking mFlusiva may need to use the finder or call around. He told MedPage Today that pharmacies have sometimes ordered standard flu vaccines without distinguishing among newer products, making certain brands harder to locate. The report does not provide a complete inventory of locations or say how many doses are available in each area.
The FDA approved mFlusiva for adults 50 and older. The approval comes amid calls from US medical groups to get flu and Covid shots. The approval was traditional for adults ages 50 to 64 and accelerated for those 65 and older, with a postmarketing effectiveness study planned for the older group. That study is intended to provide further evidence about how well the vaccine prevents illness in real-world use.
Limited Supply Shapes Vaccine Choices
The limited rollout means people who specifically want an mRNA flu vaccine may have to spend more time locating it than a standard flu shot. For many readers, the practical choice may be between waiting or searching for mFlusiva and getting another flu vaccine that is available sooner. William Schaffner, MD, of Vanderbilt University, emphasized in the MedPage Today report that people should not delay vaccination while seeking a particular product.
The evidence also affects how patients weigh their options. A phase III trial found greater immunogenicity for mFlusiva than a standard-dose comparator, but the available evidence does not establish that it provides better clinical protection than enhanced flu vaccines. Schaffner said the immune response appears superior in some respects, while stressing that whether that translates into better protection remains to be seen. The report also cites trial data showing more injection-site pain, fatigue, headache and muscle aches than with standard flu shots.
As an affiliate, we earn on qualifying purchases.
Approval Came After Pharmacy Orders
MedPage Today reported that the FDA approved mFlusiva in August 2026, after national retail pharmacy chains had placed orders for the season’s flu vaccines. That timing helps explain why the new shot is not expected to be as widely stocked as established products in its first year. The company’s stated count of more than 13,000 locations indicates distribution, but does not mean every pharmacy carries it.
U.S. flu vaccine choices include standard-dose shots, the nasal spray FluMist, and enhanced options such as Flublok, Flucelvax, Fluzone High-Dose and Fluad. The products differ in how they are made and in their formulations; some are designed for older adults. The source report says all U.S. flu vaccines are now trivalent, following the CDC’s determination that the B/Yamagata lineage had stopped circulating after March 2020.
Questions about the strength of the clinical evidence shaped the FDA review. The pivotal mFlusiva study compared it with a standard-dose vaccine, rather than an enhanced vaccine. A separate study found a stronger immune response than Fluzone High-Dose among people 65 and older, but did not measure clinical outcomes. The FDA’s approval terms call for additional effectiveness data for that age group.
““If someone wants to get mFlusiva, they’re going to have to use that website or call around.””
— Amesh Adalja, MD, Johns Hopkins Center for Health Security
As an affiliate, we earn on qualifying purchases.
Protection Versus Enhanced Vaccines
It is not yet clear whether mFlusiva provides better clinical protection than enhanced flu vaccines such as Flublok or Fluzone High-Dose. The pivotal trial used a standard-dose comparator, and the separate study in adults 65 and older measured immune response rather than illness outcomes. The FDA approval requires a postmarketing effectiveness study for the older age group, but the report does not give a completion date or results.
Local stock also changes over time, and the company’s figure of more than 13,000 locations does not specify how many doses are at each site. The report offers no pharmacy-by-pharmacy inventory or estimate of how quickly supplies may be replenished. People should confirm availability directly before traveling.
As an affiliate, we earn on qualifying purchases.
Check Local Stock Before Visiting
People seeking mFlusiva can start with Moderna’s vaccine finder and then contact a listed pharmacy or clinic to confirm stock, eligibility and appointment requirements. Those unable to find it can ask a healthcare professional or pharmacist about other available flu vaccines rather than assuming the mRNA product is the only suitable option.
Further evidence is expected through the postmarketing effectiveness study required for adults 65 and older. The report does not specify when findings will be available. For this season, Schaffner’s stated advice is to get a flu vaccine that is available rather than wait for a preferred product, particularly as influenza activity had begun early in many parts of the country, according to his comments to MedPage Today.
As an affiliate, we earn on qualifying purchases.
Key Questions
Where can I find mFlusiva?
Moderna says mFlusiva is available at more than 13,000 locations and provides a vaccine finder. Check the listing and call the location to confirm current stock before going.
Who is eligible for the mRNA flu shot?
The FDA approved mFlusiva for adults 50 and older. Its approval is traditional for ages 50 to 64 and accelerated for adults 65 and older, with an effectiveness study planned for the older group.
Why might a pharmacy not have mFlusiva?
The FDA approved the vaccine in August, after many retail pharmacy chains had ordered their flu vaccine supply for the season. Moderna also described this as a limited first-year launch.
Is mFlusiva proven to work better than other enhanced flu shots?
The evidence described in the report does not establish better clinical protection than enhanced flu vaccines. Studies found certain immune-response results, but the pivotal trial compared mFlusiva with a standard-dose vaccine, and another study did not measure clinical outcomes.
Should I wait until I find mFlusiva?
Schaffner advised people not to delay vaccination while seeking a particular product and said to get a vaccine that is available. Ask a healthcare professional or pharmacist about options suited to your circumstances.
Source: rss
Halloween Picks
halloween
As an affiliate, we earn on qualifying purchases.
